Drug Profile
Research programme: pain therapeutics - Almirall/Esteve/Palau Pharma/Proteomika
Alternative Names: Neogenius Pharma projectLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Almirall S.A.; Esteve; Palau Pharma; Proteomika
- Developer Almirall S.A.; ESTEVE; Palau Pharma; Proteomika
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Musculoskeletal pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Musculoskeletal-pain in Spain
- 02 Mar 2010 Preclinical trials in Musculoskeletal pain in Spain (unspecified route)